Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients (PEGARI)
This study has been completed.
Study NCT00221624. Last updated on June 12, 2007.
Information provided by University Hospital, Bordeaux
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HCV Infection
Hepatitis C, Chronic
Additional conditions recognized in this trial
Hepatitis
Hepatitis C
Infection
More general conditions related to this trial
Digestive System Diseases
Flaviviridae Infections
Hepatitis, Chronic
Hepatitis, Viral, Human
Liver Diseases
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
Peginterferon alfa-2a
ribavirin
amantadine
Additional drug interventions recognized in this trial
Interferon Alfa-2a
Interferons
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Dyskinesia Agents
Anti-Infective Agents
Antimetabolites
Antineoplastic Agents
Antiparkinson Agents
Antiviral Agents
Central Nervous System Agents
Dopamine Agents
Growth Inhibitors
Growth Substances
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
University Hospital, Bordeaux
Hoffmann-La Roche
Back to top of Main Content